Novartis AG
A global medicines company that researches, develops, and markets healthcare products.
NOVN | SW
Overview
Corporate Details
- ISIN(s):
- CH0012005267 (+10 more)
- LEI:
- 5493007HIVTX6SY6XD66
- Country:
- Switzerland
- Address:
- LICHTSTR. 35, 4056 BASEL
- Website:
- https://www.novartis.com/
- Sector:
- Manufacturing
Description
Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-02-25 23:55 |
Novartis issues summary financial information for the Alcon eye care business a…
|
English | 41.6 KB | ||
| 2019-01-30 16:17 |
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2018
|
English | 7.3 KB | ||
| 2019-01-30 07:00 |
Novartis delivered strong sales growth with core margin expansion, built leadin…
|
English | 129.3 KB | ||
| 2018-12-21 14:53 |
Novartis successfully completes acquisition of Endocyte
|
English | 16.7 KB | ||
| 2018-12-20 07:00 |
Novartis announces new CEO of Oncology Business Unit
|
English | 18.4 KB | ||
| 2018-11-13 22:29 |
Alcon files initial Form 20-F registration statement with SEC for proposed spin…
|
English | 22.8 KB | ||
| 2018-10-18 08:00 |
Novartis delivered strong growth and innovation during the third quarter, inclu…
|
English | 118.2 KB | ||
| 2018-08-23 08:15 |
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 …
|
English | 23.3 KB | ||
| 2018-07-27 15:53 |
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimuma…
|
English | 24.0 KB | ||
| 2018-07-18 08:00 |
Novartis delivers solid growth in second quarter and continues transformation t…
|
English | 123.0 KB | ||
| 2018-06-29 15:10 |
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressiv…
|
English | 31.5 KB | ||
| 2018-06-29 08:00 |
Novartis announces intention to seek shareholder approval for 100% spinoff of A…
|
English | 28.6 KB | ||
| 2018-06-01 15:00 |
Novartis completes sale of stake in consumer healthcare joint venture to GSK fo…
|
English | 16.8 KB | ||
| 2018-06-01 14:40 |
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevent…
|
English | 26.8 KB | ||
| 2018-05-18 02:14 |
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel tre…
|
English | 26.9 KB |
Automate Your Workflow. Get a real-time feed of all Novartis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Novartis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Novartis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-30 | N/A | Executive member | Sell | None | 1,973,993.83 CHF |
| 2025-03-07 | N/A | Non-Executive member | Buy | None | 160,000.00 CHF |
| 2025-02-11 | N/A | Executive member | Sell | None | 312,203.18 CHF |
| 2025-02-07 | N/A | Executive member | Sell | None | 2,500,278.74 CHF |
| 2025-02-05 | N/A | Executive member | Sell | None | 1,365,687.19 CHF |
| 2025-02-04 | N/A | Executive member | Sell | None | 1,840,201.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 699,424.74 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 698,883.18 CHF |
| 2024-12-19 | N/A | Executive member | Sell | None | 1.00 CHF |
| 2024-11-29 | N/A | Executive member | Sell | None | 167,294.98 CHF |
Peer Companies
